The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Stent development and local drug delivery
Open accessAbstract
Stent implantation has become the new standard angioplasty procedure. In-stent re-stenosis remains the major limitation of coronary stenting. Re-stenosis is related to patient-, lesion- and procedure-specific factors. Patient-specific factors can not be influenced to any extent. Procedure-specific factors are affected by implantation technique and stent characteristics. Design and material influence vascular injury and humoral and cellular response. Radiation has been shown to have inhibitory effects on smooth muscle cell growth and neo-intima formation, but in clinical trials the outcome has been hampered by re-stenosis at the edges of the radioactive stent ('candy wrapper'). New approaches target pharmacological modulation of local vascular biology by local administration of drugs. This allows for drug application at the precise site and time of vessel injury. Systemic release is minimal and this may reduce the risk of toxicity. The drug and the delivery vehicle must fulfil pharmacological, pharmacokinetic and mechanical requirements and the application of eluting degradable matrices seems to be a possible solution. Numerous pharmacological agents with antiproliferative properties are currently under clinical investigation, e.g. actinomycin D, rapamycin or paclitaxel. Another approach is for stents to be made of biodegradable materials as an alternative to metallic stents. Their potential long-term complications, such as in-stent re-stenosis and the inaccessibility of the lesion site for surgical revascularization, needs to be assessed. Current investigational devices and the line of (pre)clinical investigation are discussed in detail. Currently, there is little experimental, and only preliminary clinical, understanding of the acute and long-term effects of drug-eluting or biodegradable stents in coronary arteries. The clinical benefit of these approaches still has to be proven.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Promotion of microtubule assembly in vitro by taxol
SCHIFF, P. B., FANT, J., & HORWITZ, S. B. (1979) · Nature · doi:10.1038/277665a0 · Cited by 3,600
Rowinsky, E. K., & Donehower, R. C. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321507 · Cited by 1,924
Cited by
Serruys, P. W., Kutryk, M. J. B., & Ong, A. T. L. (2006) · New England Journal of Medicine · doi:10.1056/nejmra051091 · Cited by 762
Self-citationHong, Y. J., Jeong, H., Cho, K. W., Lu, N., & Kim, D. (2019) · Advanced Functional Materials · doi:10.1002/adfm.201808247 · Cited by 559
Frost, M. C., Reynolds, M. M., & Meyerhoff, M. E. (2005) · Biomaterials · doi:10.1016/j.biomaterials.2004.06.006 · Cited by 343
The Road to Bioabsorbable Stents: Reaching Clinical Reality?
Erne, P., Schier, M., & Resink, T. J. (2006) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-004-0341-9 · Cited by 249
Biodegradable bone implants as a new hope to reduce device-associated infections-a systematic review
Paiva, J. C. C., Oliveira, L., Vaz, M. F., & Costa-de-Oliveira, S. (2022) · Bioengineering · doi:10.3390/bioengineering9080409 · Cited by 53
Metadata
- Authors
- Regar, E., Sianos, G., & Serruys, P. W.
- Venue
- British Medical Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2001-10-01
- Volume
- 59
- Issue
- 1
- Pages
- 227-248
- ISSN
- 0007-1420 (ISSN-L)
- 1471-8391
- OpenAlex
- W2060790398
- Cited by
- 158
- References
- 2
- FWCI
- 5.90
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Stent development and local drug delivery. https://app.cochat.ai/papers/10.1093/bmb/59.1.227
- The paper
- Regar, E., Sianos, G., & Serruys, P. W. (2001). Stent development and local drug delivery. British Medical Bulletin. https://doi.org/10.1093/bmb/59.1.227
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.